Emergent BioSolutions Inc. EBS

Latest FY: 2025 Healthcare Drug Manufacturers - Specialty & Generic
Market Price $4.60
Market Cap $230.22M
P/E Ratio 4.95
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↓-28.8% YoY
$742.90M
3-Yr CAGR: -12.7%
Net Income ↑127.6% YoY
$52.60M
Net Margin: 7.1%
Free Cash Flow ↑338.0% YoY
$156.80M
FCF Yield: 68.11%
EPS (Diluted) ↑125.8% YoY
$0.93
Basic: $0.98
Return on Equity Efficiency
10.1%
ROA: 203.9%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (EBS)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $488.8M $357.5M $51.8M $1.13 $53.5M $-22.8M
FY 2017 $560.9M +14.7% $365.2M $82.6M +59.5% $1.71 +51.3% $208.1M $153.3M +773.3%
FY 2018 $782.4M +39.5% $460.1M $62.7M -24.1% $1.22 -28.7% $41.8M $-30.3M -119.8%
FY 2019 $1,106.0M +41.4% $672.5M $54.5M -13.1% $1.04 -14.8% $188.0M $101.1M +433.7%
FY 2020 $1,555.4M +40.6% $1,031.4M $305.1M +459.8% $5.67 +445.2% $536.0M $395.0M +290.7%
FY 2021 $1,792.7M +15.3% $701.0M $230.9M -24.3% $4.27 -24.7% $321.1M $96.1M -75.7%
FY 2022 $1,117.5M -37.7% $383.0M $-211.6M -191.6% $-4.22 -198.8% $-34.1M $-149.9M -256.0%
FY 2023 $1,049.3M -6.1% $317.6M $-760.5M -259.4% $-14.85 -251.9% $-206.3M $-257.9M -72.0%
FY 2024 $1,043.6M -0.5% $199.3M $-190.6M +74.9% $-3.60 +75.8% $58.7M $35.8M +113.9%
FY 2025 $742.9M -28.8% $416.7M $52.6M +127.6% $0.93 +125.8% $170.6M $156.8M +338.0%
$

Valuation

Market Price $4.60
Market Cap $230.22M
Enterprise Value $596.92M
P/E Ratio 4.95
P/B Ratio 0.45
FCF Yield 68.11%
Dividend Yield N/A
Shares Outstanding 51,273,335
%

Profitability & Margins

Gross Margin 56.09%
Operating Margin 13.47%
Net Margin 7.08%
Return on Equity (ROE) 10.07%
Return on Assets (ROA) 203.88%
Asset Turnover 28.79x
Revenue 3-Yr CAGR -12.72%
🛡️

Financial Health & Liquidity

Current Ratio 2.11
Cash Ratio 16.84
Debt / Equity 1.095
Debt / Assets 22.174
Cash & Equivalents $205.40M
Total Debt $572.10M
Book Value / Share $10.19
💧

Cash Flow Efficiency

Operating Cash Flow $170.60M
Capital Expenditures (CapEx) $13.80M
Free Cash Flow $156.80M
OCF / Revenue 22.96%
FCF / Revenue 21.11%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $0.93
EPS (Basic) $0.98
Dividends / Share N/A
Book Value / Share $10.19
EPS YoY Growth 125.83%
🏛️

Balance Sheet (FY 2025)

Total Assets $25.80M
Total Liabilities $12.20M
Stockholders' Equity $522.60M
Current Assets $25.80M
Current Liabilities $12.20M